News
Novo Nordisk A/S. Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback